

Arun Swaminath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8854003/publications.pdf>

Version: 2024-02-01

84
papers

2,067
citations

304602

22
h-index

243529

44
g-index

86
all docs

86
docs citations

86
times ranked

2806
citing authors

#	ARTICLE	IF	CITATIONS
1	CX3CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. <i>Journal of Experimental Medicine</i> , 2014, 211, 1571-1583.	4.2	320
2	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-to Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016, 111, 1147-1155.	0.2	257
3	Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 645-656.	1.9	121
4	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.2	119
5	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2026-2033.	0.9	118
6	A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. <i>Gastroenterology</i> , 2021, 161, 837-852.e9.	0.6	113
7	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
8	Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 213-216.	0.9	89
9	Fatigue in Inflammatory Bowel Diseases: Etiologies and Management. <i>Advances in Therapy</i> , 2020, 37, 97-112.	1.3	63
10	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	2.4	60
11	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2461-2467.	0.9	50
12	Video capsule endoscopy in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1254-1262.	0.9	48
13	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 669-681.	1.9	48
14	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
15	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	2.4	44
16	The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 427-435.	0.9	36
17	Infliximab-Induced Autoimmune Hepatitis with Successful Switch to Adalimumab in a Patient with Crohn's disease: The Index Case. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3386-3388.	1.1	35
18	Peripheral Neuropathic Symptoms in Celiac Disease and Inflammatory Bowel Disease. <i>Journal of Clinical Neuromuscular Disease</i> , 2012, 13, 137-145.	0.3	33

#	ARTICLE	IF	CITATIONS
19	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
20	Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 113.	0.6	28
21	Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1673-1681.	2.4	25
22	Review of inflammatory bowel disease and COVID-19. <i>World Journal of Gastroenterology</i> , 2020, 26, 5534-5542.	1.4	25
23	Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn's Disease: A US National Practice Survey Comparing Experts and Non-Experts. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1160-1164.	1.1	21
24	Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With <i>Clostridium difficile</i> . <i>Inflammatory Bowel Diseases</i> , 2019, 25, 775-781.	0.9	17
25	488 Early Institution of Tinidazole May Prevent Pouchitis Following Ileal-Pouch Anal Anastomosis (IPAA) Surgery in Ulcerative Colitis (UC) Patients. <i>Gastroenterology</i> , 2010, 138, S-69.	0.6	13
26	Refractory Urticarial Vasculitis as a Complication of Ulcerative Colitis Successfully Treated With Rituximab. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 281-283.	0.5	13
27	Optimizing drug therapy in inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2007, 9, 513-520.	1.1	12
28	TNF-alpha antagonist induced lupus on three different agents. <i>Postgraduate Medicine</i> , 2017, 129, 304-306.	0.9	12
29	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	0.9	11
30	Cost-effectiveness of QuantiFERON Testing Before Initiation of Biological Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2444-2449.	0.9	10
31	The Power of Poop: Patients Getting Ahead of Their Doctors Using Self-Administered Fecal Transplants. <i>American Journal of Gastroenterology</i> , 2014, 109, 777-778.	0.2	10
32	The Course of SARS-COV2 Infection Was Not Severe in a Crohn's Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection. <i>Antibodies</i> , 2020, 9, 42.	1.2	10
33	When combination therapy isn't working: Emerging therapies for the management of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1139.	1.4	10
34	Internet Searches About Therapies Do Not Impact Willingness to Accept Prescribed Therapy in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1013-1020.	1.1	9
35	DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S036-S036.	0.6	9
36	SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares. <i>American Journal of Gastroenterology</i> , 2021, 116, 2480-2481.	0.2	9

#	ARTICLE	IF	CITATIONS
37	Presentation and outcomes among inflammatory bowel disease patients with concurrent pneumatosis intestinalis: a case series and systematic review. <i>Intestinal Research</i> , 2020, 18, 289-296.	1.0	9
38	Role of Hospital Teaching Status on Outcomes of Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2216-2226.	1.1	8
39	Mortality Risk of Inflammatory Bowel Disease: A Caseâ€“Control Study of New York State Death Records. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1604-1611.	1.1	7
40	Obesity in Inflammatory Bowel Disease Is Associated with Early Readmissions Characterised by an Increased Systems and Patient-level Burden. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1807-1815.	0.6	7
41	COVID-19 Vaccination and Inflammatory Bowel Disease: Desired Antibody Responses, Future Directions, and a Note of Caution. <i>Gastroenterology</i> , 2022, 162, 349-350.	0.6	7
42	Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4851-4865.	1.1	6
43	Endo-hepatology: An emerging field. <i>World Journal of Gastrointestinal Endoscopy</i> , 2021, 13, 296-301.	0.4	5
44	Effect of Physician Education and Patient Counseling on Inpatient Nonsurgical Percutaneous Feeding Tube Placement Rate, Indications, and Outcome. <i>Southern Medical Journal</i> , 2010, 103, 126-130.	0.3	5
45	The Comb Sign in Crohnâ€™s Ileocolitis. <i>Journal of General Internal Medicine</i> , 2018, 33, 773-773.	1.3	4
46	Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians. <i>Advances in Therapy</i> , 2021, 38, 4152-4161.	1.3	4
47	An unusual case of diarrhea. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 436-437.	0.5	3
48	A rare endoscopic finding: severely ulcerated giant sigmoid diverticulum. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1159-1160.	0.5	3
49	Management of iatrogenic perforation during colonoscopy in ulcerative colitis patients: a survey of gastroenterologists and colorectal surgeons. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1607-1616.	1.0	3
50	Increased Mortality and Healthcare Costs Upon Hospital Readmissions of Ulcerative Colitis Flares: A Large Population-Based Cohort Study. <i>Crohn's & Colitis 360</i> , 2021, 3, .	0.5	3
51	The influence of hiv coinfection on the natural history of hcv infection. <i>Current Hepatitis Reports</i> , 2005, 4, 131-137.	0.3	2
52	Patient considerations in the management of ulcerative colitis – role of vedolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1235.	0.9	2
53	Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium. <i>Gastroenterology</i> , 2016, 150, S974.	0.6	2
54	Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice. <i>Gastroenterology</i> , 2016, 150, S392-S393.	0.6	2

#	ARTICLE	IF	CITATIONS
55	From Bad to Worse: The Relationship Between Opioid Use and Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1188-1189.	0.6	2
56	Impact of inflammatory bowel disease on hospital outcomes in acute ischemic stroke: a nationwide cohort study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1759-1764.	1.0	2
57	Safety of biologics in inflammatory bowel disease patients with COVID-19. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2051-2055.	1.0	2
58	Patient With Ulcerative Colitis and Failure of Ustekinumab Responds to Risankizumab: Similar Is Not Identical. <i>Inflammatory Bowel Diseases</i> , 2022, 28, e140-e141.	0.9	2
59	W1199 Risk of Developing Anti-TNF Alpha Induced Psoriasis Among Patients With Crohn's Disease: Are All Anti-TNFS Equal?. <i>Gastroenterology</i> , 2010, 138, S-672.	0.6	1
60	Tu1294 Impact of the Internet on Willingness to Accept Prescribed Therapy in Inflammatory Bowel Disease Patients. <i>Gastroenterology</i> , 2012, 142, S-795.	0.6	1
61	Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice. <i>Gastroenterology</i> , 2016, 150, S393.	0.6	1
62	Hepatic Masses in a Patient With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, e5-e6.	0.6	1
63	Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19. <i>Gastroenterology Research</i> , 2021, 14, 324-333.	0.4	1
64	<i>Clostridiodes difficile</i> Treatment Guided by Polymerase Chain Reaction Stool Testing Does not Alter Outcomes for Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 572-574.	0.6	1
65	The mismatch repair (MMR) protein hMSH3 is lost from polyp epithelium of patients with PTEN germline hamartomatous syndromes. <i>Gastroenterology</i> , 2003, 124, A42.	0.6	0
66	Fulminant Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2010, 362, 635-635.	13.9	0
67	596 Increased Risk of Surgery After Attenuation of Anti-TNF± Therapy for Crohn's Disease. <i>Gastroenterology</i> , 2010, 138, S-856.	0.6	0
68	Microbial Regulation of CD14+ Human Intestinal DCs Support ILC Production of IL-22 in IBD. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S11.	0.9	0
69	Microbial Regulation of CD141 Human Intestinal DCs Support ILC Production of IL-22 in IBD. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S107-S108.	0.9	0
70	866 Microbiota Support Increased Production of IL-22 by Lamina Propria Innate Lymphoid Cells in Patients With IBD. <i>Gastroenterology</i> , 2012, 142, S-149.	0.6	0
71	23 TLR/MYD88-Dependent Production of IL11 ² and IL-23 by Intestinal Dendritic Cells Support Increased ILC Production of IL-22 in IBD. <i>Gastroenterology</i> , 2013, 144, S-7.	0.6	0
72	Tu1172 Mortality and Cause of Death in Crohn's Disease in NYC, 1993-2010. <i>Gastroenterology</i> , 2014, 146, S-773-S-774.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Mo1810 Gut Microbiome Characteristics of IBD Patients Undergoing Induction of Biologic Therapy. <i>Gastroenterology</i> , 2015, 148, S-716-S-717.	0.6	0
74	Tu1972 The Use of Fecal Calprotectin to Understand the Expanded Utility of IBD Clinical Disease Activity and Quality of Life Assessments in Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, S994.	0.6	0
75	Sa2083 Using Humanized Germ-Free Mice to Understand Microbiome Variation in IBD Patients Who Respond to Anti-TNF Medications. <i>Gastroenterology</i> , 2016, 150, S1268.	0.6	0
76	Mo1864 Current Trends in the Quality of Care of Inflammatory Bowel Disease in the United States. <i>Gastroenterology</i> , 2016, 150, S799.	0.6	0
77	Tu1093 Enteral Nutrition Therapy for the Induction of Crohn's Disease in the Pediatric Population: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S840.	0.6	0
78	Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1026-1027.	1.9	0
79	Radiology Prep to the Rescue: Radiocontrast Enema After Failure of Oral Bowel Preparation for Patients with an Ileocolonic Fistula. <i>American Journal of Gastroenterology</i> , 2017, 112, 1363.	0.2	0
80	Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1121-1121.	1.9	0
81	Increasing Pediatricians' Awareness of the Association between Anal Skin Tags and Earlier Diagnosis of Crohn's Disease. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 40-42.	0.8	0
82	P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S433-S433.	0.6	0
83	Unusual cause of lower gastrointestinal bleed and abdominal pain. <i>Frontline Gastroenterology</i> , 2020, 11, 337-338.	0.9	0
84	Impatience with Inpatients: Are Hospitalization Rates Declining for IBD Patients?. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	0